DART Therapeutics appoints executive team

Friday, September 14, 2012 01:51 PM

DART Therapeutics, a Cambridge, Mass.-based new-model biotechnology firm focused on developing therapies for Duchenne Muscular Dystrophy (DMD), has appointed an executive team. Members include co-founder and executive chairman Eugene W. Williams with the new title of CEO, Ernest D. Bush, PhD, as chief scientific officer., Dr. Elliot Goldstein as chief medical officer, and Cabot Brown as chief financial officer.

Williams bring more than 25 years of experience as a senior manager at major biotech firms, including Genzyme, an innovator and pioneer in pediatric rare diseases, as well as experience serving as founder/executive chairman of numerous entrepreneurial life sciences ventures. He brings experience and accomplishment in pediatric rare diseases, global development, business development, portfolio management and entrepreneurship.

Bush has more than 30 years of experience in biomedical R&D for major pharmaceutical companies, including Hoffman La-Roche, where he was responsible for the preclinical safety department at Nutley, N.J., as well as the non-clinical assessment of in-licensing candidates.

Goldstein brings more than 25 years of executive-level pharmaceutical and biotechnology expertise to DART with senior management roles at Sandoz, Novartis, SB (now GSK) and Maxygen.

Brown has co-founded several advisory and investment banking firms, including Carabiner, Seven Hills Group and Brown, McMillan & Co. Brown has spent more than 25 years working as an advisor to and investor in numerous companies across many segments of the healthcare industry.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 17

PPD, Medidata join their technologies for risk-based monitoring, adaptive trial design

ERT acquires eClinical Insights in "strategic combination" to gain cloud-based trial software platform, expertise

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs